408 completed, 53 unknown, 46 recruiting, 45 terminated. 616 Phase 2, 87 Phase 1, 67 Phase 3.
Follow Gram-Positive Bacterial Infections: new trials by email Literature Review of Gram-Positive Bacterial Infections trials Research Report on Gram-Positive Bacterial Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2027-02-01 | 2026-11-02 |
| Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB ID93 + GLA-SE vaccine, Placebo vaccine - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 1500 | 2027-01-31 | 2026-08-24 |
| A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization Resistant Potato Starch, Maltodextrin - Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA) | Phase 2 | Not yet recruiting | VA Office of Research and Development | 120 | 2027-01-01 | 2026-08-28 |
| Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin Vancomycin (POC) - Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium | Phase 2 / Phase 3 | Withdrawn | University of Maryland, Baltimore | 2027-01-01 | 2026-07-29 | |
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV Rifapentine, Isoniazid, Dolutegravir - Tuberculosis | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 144 | 2026-09-28 | 2026-11-02 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older Vaccination with rBCG-N-RSV, Vaccination with conventional BCG (BCG-WT) - Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention | Phase 2 | Recruiting | Biothervax SpA | 200 | 2026-09-14 | 2026-09-15 |
| Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus Topical anti-Staphylococcus bacteriophage therapy, Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy - Diabetic Foot, Staphylococcal Infections | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 60 | 2026-09-01 | 2026-03-20 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus Anifrolumab + APFS - Systemic Lupus Erythematosus | Phase 2 | Recruiting | AstraZeneca | 24 | 2026-08-31 | 2026-10-28 |
| Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial Omega-3 (EPA+DHA), Placebo - Tuberculosis, Inflammation Biomarkers | Phase 2 | Recruiting | North-West University, South Africa | 40 | 2026-08-19 | 2026-09-09 |
| A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Tdap vaccine, Placebo - Pertussis (Whooping Cough), Diphtheria | Phase 2 | Recruiting | Changchun BCHT Biotechnology Co. | 420 | 2026-08-12 | 2026-10-26 |
| BPaLMZ for TB Meningitis BPaLMZ Regimen - Tuberculous Meningitis, HIV | Phase 2 | Recruiting | David Boulware | 312 | 2026-07-28 | 2026-10-16 |
| Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB sorfequiline, Pretomanid, Linezolid - Tuberculosis, Pulmonary | Phase 2 | Recruiting | Global Alliance for TB Drug Development | 100 | 2026-07-09 | 2026-08-19 |
| BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children 4-month FDC-based regimen, 3-month BDCZ regimen, Standard 6-month treatment regimen - Tuberculosis | Phase 2 | Recruiting | Huashan Hospital | 90 | 2026-07-08 | 2026-10-26 |
| Oritavancin for Treatment of Serious Cardiac Infections Oritavancin - Infective Endocarditis, Cardiac Device Infection | Phase 2 | Not yet recruiting | Kirby Institute | 20 | 2026-07-01 | 2026-04-29 |
Showing 20 of 616. Sign in to see all of them.
Tuberculosis (194) · Tuberculosis, Pulmonary (91) · Clostridium Infections (56) · Staphylococcal Infections (47) · Tetanus (45) · Pneumococcal Infections (43) · Diphtheria (35) · HIV Infections (35) · Tuberculosis, Multidrug-Resistant (33) · Streptococcal Infections (27) · Haemophilus Infections (23) · Hepatitis B (23) · Whooping Cough (22) · Poliomyelitis (21) · Mycobacterium Infections, Nontuberculous (20)
Bacterial Infections and Mycoses (615) · Infections (607) · Bacterial Infections (604) · Actinomycetales Infections (366) · Mycobacterium Infections (315) · Respiratory Tract Diseases (146) · Respiratory Tract Infections (133) · Lung Diseases (116) · Tuberculosis (83) · Virus Diseases (71) · Blood-Borne Infections (67) · Pathological Conditions, Signs and Symptoms (67) · Streptococcal Infections (67) · Communicable Diseases (66)
Rifampin (61) · Isoniazid (56) · Pyrazinamide (43) · Ethambutol (41) · bedaquiline (41) · Linezolid (34) · Moxifloxacin (32) · 13-valent pneumococcal vaccine (26) · Vancomycin (24) · OPC-67683 (23) · pretomanid (22) · rifapentine (17) · Rifabutin (14) · Clofazimine (13) · Fecal Microbiota Transplantation (13)
National Institute of Allergy and Infectious Diseases (NIAID) (43) · GlaxoSmithKline (41) · Pfizer (13) · Centers for Disease Control and Prevention (12) · Global Alliance for TB Drug Development (12) · Merck Sharp & Dohme LLC (10) · Aeras (9) · Johns Hopkins University (9) · Sanofi Pasteur, a Sanofi Company (8) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (6) · Beijing Chest Hospital (6) · Michael Hoelscher (6) · Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · TASK Applied Science (6) · University Medical Center Groningen (6)
United States (179) · South Africa (131) · Canada (50) · Uganda (36) · China (33) · Philippines (28) · Tanzania (26) · Brazil (20) · France (20) · United Kingdom (20) · South Korea (18) · Thailand (17) · India (16) · Peru (16) · Spain (16)
Andreas Diacon, MD (5) · Rodney Dawson, MD (5) · Susan Dorman, MD (4) · Bolanle A Omotoso, MD (3) · Clifton E Barry, Ph.D. (3) · G. Ralph Corey, MD (3) · Kelly Dooley, MD (3) · Kelly Dooley, MD, PhD (3) · Kevin L Winthrop, MD, MPH (3) · Marc Weiner, MD (3)
PMID 33542052, PMID 20657177, PMID 26647431, PMID 28340322, PMID 30102705, PMID 30689507, PMID 34021314, PMID 36730240, PMID 36808186, PMID 37035978, PMID 38768617, PMID 41245385, PMID 42286373, PMID 10440607, PMID 10526739, PMID 106465, PMID 11171619, PMID 11202234, PMID 12045127, PMID 15079177, PMID 15302746, PMID 15844071, PMID 15844073, PMID 15882530, PMID 16012514, PMID 16141439, PMID 16574936, PMID 16675781, PMID 16776446, PMID 17391816, PMID 17517835, PMID 17879915, PMID 17893153, PMID 18070980, PMID 18230259, PMID 18470901, PMID 18505852, PMID 18672531, PMID 18713501, PMID 18787216, PMID 18799552, PMID 19236695, PMID 19345831, PMID 19406981, PMID 19494215, PMID 19564361, PMID 19753300, PMID 19923475, PMID 20089970, PMID 20118767
2023 (6), 2009 (4), 2016 (4), UM1AI068636 (4), 2008 (3), 2014 (3), 2019 (3), 2025 (3), 2015 (2), U01AI068632 (2), U01AI068636 (2), 2005 (1), 2017 (1), 2018 (1), 5UM1AI104681-12 (1)